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Thepathogenesisofﬁbrosisinhepaticcirrhosisremainsobscure.Thisstudyexaminestheeventualroleofangiogenicfactorsinthe
ﬁbrotic process. A series of 55 cirrhotic livers was studied for the proliferation state of ﬁbroblasts, and the expression of vascular
endothelial growth factor (VEGF), thymidine phosphorylase (TP) and the basic and acidic ﬁbroblast growth factor (bFGF, aFGF)
in both ﬁbroblasts and hepatic cells. The angiogenic and/or ﬁbrogenic factors VEGF, TP, bFGF, and aFGF were clearly expressed
in regenerative hepatocytes, but not in ﬁbroblasts of diﬀuse hepatic ﬁbrosis. The immunohistochemical ﬁndings suggest that an-
giogenic factors and factors promoting oxidative stress (i.e., TP) produced by hepatocytes may contribute to the development of
ﬁbrous bands in hepatic cirrhosis.
Copyright © 2007 Alexandra Giatromanolaki et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Cirrhosis is characterized by diﬀuse hepatic ﬁbrosis, in the
form of delicate bands or broad scars, replacing the normal
lobular architecture and encompassing regenerative nodules
of hepatocytes. Most cases of cirrhosis are attributable to al-
coholicliverdiseaseandchronicviralhepatitis,whilelessfre-
quent causes include autoimmune hepatitis, biliary disease,
drugs, hemochromatosis, Wilson’s disease, α1-antitrypsin
deﬁciency, and galactosemia and tyrosinemia in infants and
children.
The molecular events leading to ﬁbrotic process remain,
by and large, obscure in hepatic cirrhosis. The highly vascu-
larized ﬁbrous tissue, surrounding the regenerative hepatic
nodules, suggests that angiogenic factors may be involved in
the pathogenesis of the disease. Experimental data support
such a hypothesis and angiogenic factors expressed by hep-
atocytes have been implicated as a key event in the develop-
ment of hepatic ﬁbrosis [1–3].
In the current study, we investigated the expression of
angiogenic and ﬁbrogenic growth factors in cirrhotic livers,
providing evidence that the overproduction of these factors
by hepatocytes, but not stromal cells, may play an important
role in the pathogenesis of the disease.
2. MATERIALS AND METHODS
Formalin-ﬁxed paraﬃn-embedded tissues from biopsies of
55 patients with fully developed micronodular cirrhosis were
retrieved from the archives of the Department of Pathology,
Democritus University of Thrace Medical School, Alexan-
droupolis, Greece. All cases were of a posthepatitic etiology
for the patients having a long-standing history of chronic vi-
ral hepatitis B with a histological activity index ranging from
11 to 18. Furthermore, the cirrhotic livers were characterized
by the presence of an ongoing necroinﬂammation, mainly in
the form of piecemeal necrosis. There was, however, no ev-
idence of large-cell or small-cell liver cell dysplasia and no
indication of hepatocellular carcinoma.
A standard immunohistochemical technique, with the
appropriate antibodies and controls, was applied (a) to as-
sess the proliferation state of ﬁbroblasts and (b) to detect
theexpressionofvariousangiogenicandﬁbrogenicfactors—
the vascular endothelial growth factor (VEGF), the thymi-
dine phosphorylase (TP), and the basic and acidic ﬁbroblast
growth factors (bFGF, aFGF). Details of the immunohisto-
chemical techniques [4, 5] and the primary antibodies used
are shown in Table 1.
Immunohistochemical evaluation was performed by two
observers (GA, SE) over the conference microscope. The2 Mediators of Inﬂammation
Table 1: Details of the antibodies, dilutions, and antigen retrieval methods used in this study, MW = microwave heating.
Primary antibody Dilution/incubation time Antigen retrieval Speciﬁcity Source
VG1 1 : 4 (75 mina) MW VEGF Oxford University
P-GF.44C 1 : 4 (75mina) MW TP Oxford University
FGF-2 (147): sc-79 1 : 100 (75mina) MW bFGF Santa Cruz Biotechnology, Inc.
FGF-1 (C-19): sc-1884 1 : 100 (75mina) MW aFGF Santa Cruz Biotechnology, Inc.
MIB1 1 : 75 (75mina) MW Ki-67 antigen DAKO, Glostrup, Denmark
aAt room temperature.
extent (diﬀuse versus focal) and the intensity (strong ver-
sus weak versus absent) of the cytoplasmic and/or nuclear
expression of the proteins analyzed were recorded at ×200
magniﬁcation.
3. RESULTS
Basic ﬁbroblast growth factor (bFGF), aFGF, and VEGF were
expressed diﬀusely and uniformly in the cytoplasm of hep-
atocytes throughout the entire cirrhotic liver. In all cases,
the intensity of staining was weak, but deﬁnitely present (in
100% of cases examined). In contrast, the adjacent stromal
ﬁbroblasts and hepatocytes from normal liver samples were
persistently negative. Occasionally, small blood vessels were
positively stained.
Thymidine phosphorylase (TP), a marker of oxidative
stress, was expressed strongly to a varying extent by hepa-
tocytes. Nuclear and cytoplasmic expression was noted in 42
out of 55 cases, ranging between 5%–80% of cells examined.
In 19 out of 55 (34.5%) cases, the TP expression in hepa-
tocytes was prominent (more than 50% of hepatocytes were
stained). Again, the stroma was negative. Hepatocytes from
normal liver showed a weak staining for TP.
The MIB1 proliferation index was of a very low prolifer-
ation activity in ﬁbroblasts. Staining was noted in 14 out of
55 cases, with a percentage of positivity not exceeding 2%.
Similarly, proliferating activity of hepatocytes was low, rang-
ing from 0% to 5%. MIB1 staining was noted in 22 out of 55
cases (40%), where 6 out of 55 (11%) exhibited a relatively
high expression (5% of the total hepatocyte population ex-
amined).
Therewasnoassociationofpatternsofexpressionamong
the molecular features examined, nor with MIB1 prolifera-
tion index.
Figure 1showscharacteristicimmunostainingimagesin-
dicating the expression patterns of the above proteins.
4. DISCUSSION
There is experimental evidence that VEGF plays an impor-
tant role in the development of hepatic cirrhosis. Rosmor-
duc et al., using rats as experimental models, indicated that
biliary cirrhosis is associated with hepatocellular hypoxia
[2]. VEGF is known to be induced under hypoxic condi-
tions, as a result of a transcriptional activation of the VEGF
gene mediated by the hypoxia-driven increased HIF1α pro-
tein accumulation [6]. Rats treated with diethylnitrosamine,
an agent inducing chemical cirrhosis, show progressive liver
ﬁbrosis accompanied by increased expression of VEGF and
VEGF-receptor and active angiogenesis [1] Similarly, Yoshiji
et al., using an experimental model of chemical induction of
hepatic cirrhosis, associated the development of liver ﬁbro-
sis with a signiﬁcant increase of VEGF mRNA expression in
the liver [7]. Administration of neutralizing monoclonal an-
tibodiesagainstVEGFreceptorssuppressedangiogenesisand
signiﬁcantly reduced the development of ﬁbrosis.
The above experimental evidence is conﬁrmed in our
histopathological study, as VEGF was overexpressed in cir-
rhotic hepatocytes compared to normal liver cells. This ﬁnd-
ing is also in accordance with Shi’s et al. recent report [8].
In another study by Li et al., VEGF levels, measured in
the plasma of patients and healthy controls, showed a 1.5-
fold increase in cirrhotic patients [9]. Spider angiomas, fre-
quently noted in cirrhotic patients, were more frequent in
patients with high VEGF plasma levels, consistent with the
VEGF angiogenic activity.
The expression of both acidic and basic ﬁbroblast growth
factors was also found increased in regenerative cirrhotic
hepatocytes. The importance of these factors in the develop-
mentofthediseasehasbeenpreviouslyproposedinthestudy
of Li et al., where high bFGF plasma levels paralleled high
VEGF levelsin cirrhotic patients [9]. bFGF has a broadrange
of activity on both hepatocytes and stromal cells via speciﬁc
receptors, as shown by Huang et al. [10] .Ap o t e n ts y n e r g y
of VEGF and bFGF receptors activation in inducing angio-
genesis was noted. Using aFGF and bFGF deﬁcient mice, Yu
et al. showed that liver ﬁbrosis, resulting from chronic expo-
sure to carbon tetrachloride, was dramatically decreased in
these mice compared to controls [3].
In contrast to hepatocytes, ﬁbroblasts were totally unre-
active to the above angiogenic factors. Moreover, the pro-
liferation index, as assessed with the MIB1 monoclonal an-
tibody, was very low. These ﬁndings show that the ﬁbrotic
process, as it occurs in the context of cirrhosis, represents a
slow ﬁbroblastic response to external stimuli, that is, VEGF
and FGF, produced by hepatocytes. Altered ﬁbroblast bi-
ology, through activation of such genes, does not seem to
contribute to the process. This suggestion is further sup-
ported by the absolute lack of expression of thymidine phos-
phorylase in ﬁbroblasts, a marker of DNA synthesis and ofAlexandra Giatromanolaki et al. 3
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Figure 1: Immunohistchemical study of liver cirrhosis: (a) MIB1 nuclear staining in hepatocytes; (b) granular cytoplasmic expression of
bFGF in hepatocytes; (c) thymidine phosphorylase expression in the cytoplasm and nuclei of hepatocytes ; (d) cytoplasmic expression of
VEGF in hepatocytes. The adjacent ﬁbrous bands do not express any of these proteins.
oxidative stress [11]. TP is frequently upregulated in actively
proliferating ﬁbroblasts, that is, in the context of neoplasia
[12, 13].
It is concluded that growth factors such as VEGF, aFGF,
and bFGF produced by hepatocytes in patients with liver cir-
rhosis may have an important role in the development of
hepatic ﬁbrosis through progressive stimulation of ﬁbrob-
lasts.
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